Elizabeth Plimack, MD

Articles by Elizabeth Plimack, MD

Non-Clear Cell RCC: Key Learnings and Future Research Directions

ByElizabeth Plimack, MD,Benjamin L. Maughan, MD, PharmD,Martin H. Voss, MD

March 26th 2024

The panel discusses key learnings from recent studies in non-clear cell RCC subtypes and the need to better understand disease biology to develop optimized, histology-specific therapies rather than extrapolating clear cell treatment approaches.

Frontline Therapy for Patients With Non-Clear Cell RCC

ByElizabeth Plimack, MD,Benjamin L. Maughan, MD, PharmD,Martin H. Voss, MD

March 19th 2024

Martin Voss, MD, reviews data updates from ASCO GU 2024 on the KEYNOTE-B61 study of lenvatinib + pembrolizumab in nccRCC in addition to real-world outcomes in patients with chromophobe RCC.

Treating Patients with RCC and Brain, Liver, or Bone Metastases

ByElizabeth Plimack, MD,Benjamin L. Maughan, MD, PharmD,Martin H. Voss, MD

March 19th 2024

Panelists discuss systemic therapy approaches for RCC patients presenting with brain, liver, or bone metastases, noting more limited efficacy of IO-IO therapy in brain metastases and tendencies to use IO-TKI therapy for aggressive or rapidly progressing disease.

Managing Immune-Related Toxicities with Frontline RCC Therapies

ByElizabeth Plimack, MD,Benjamin L. Maughan, MD, PharmD,Martin H. Voss, MD

March 12th 2024

Expert panelists discuss the importance of rapid improvement within 24-72 hours with steroids for managing unpredictable immune-related toxicities that can occur with frontline IO-IO or IO-TKI regimens for patients with RCC.

Treatment Decisions for Favorable Risk RCC

ByElizabeth Plimack, MD,Benjamin L. Maughan, MD, PharmD,Martin H. Voss, MD

March 12th 2024

The panel discusses long-term data showing more limited benefit of IO-IO therapy versus TKI regimens for favorable risk RCC patients and implications for their risk-adapted treatment approach.

Frontline Treatment Approaches for Advanced Clear Cell RCC

ByElizabeth Plimack, MD,Benjamin L. Maughan, MD, PharmD,Martin H. Voss, MD

March 5th 2024

The panelists summarize their approaches to choosing frontline treatment for advanced clear cell RCC, balancing long-term and short-term efficacy data on IO-IO versus IO-TKI regimens based on recent study results.

Network Meta-Analysis Comparing Efficacy of Lenvatinib Plus Pembrolizumab to Other First Line Treatments for Metastatic Clear Cell RCC

ByElizabeth Plimack, MD,Benjamin L. Maughan, MD, PharmD,Martin H. Voss, MD

March 5th 2024

Elizabeth Plimack, MD, reviews a network meta-analysis comparing progression free survival and overall survival outcomes for lenvatinib plus pembrolizumab versus other first line regimens for metastatic clear cell renal cell carcinoma across multiple trials.

Subgroup Analysis from CLEAR Trial: Efficacy Outcomes by Baseline Tumor Size in Treatment of Metastatic Clear Cell RCC

ByElizabeth Plimack, MD,Benjamin L. Maughan, MD, PharmD,Martin H. Voss, MD

February 27th 2024

Benjamin Maughan, MD, PharmD, examines efficacy outcomes from the CLEAR trial of lenvatinib plus pembrolizumab vs sunitinib in metastatic clear cell RCC, including how overall survival, progression free survival, and response rates compare across different baseline tumor size groups.

Long Term Follow Up Data From Checkmate 214 on Nivolumab Plus Ipilimumab in First Line Clear Cell RCC

ByElizabeth Plimack, MD,Benjamin L. Maughan, MD, PharmD,Martin H. Voss, MD

February 27th 2024

Elizabeth Plimack, MD, discusses the long term follow up data from the Checkmate 214 study evaluating nivolumab plus ipilimumab versus sunitinib in first line treatment of clear cell renal cell carcinoma, including overall survival, progression free survival, response rates, and safety data.